Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Aspirin, COX-2 Inhibitors Effective as Adjuvant Therapy in Stage III Colon Cancer
Medscape, 5-16-05

Researchers at the Dana-Farber Cancer Institute have found that

Patients with stage III colon cancer may benefit from aspirin as much as from surgery and standard chemotherapy alone. A preliminary study found aspirin contributed to an additional 50% reduction in risk of recurrence and death when used as adjuvant therapy in these patients. The prospective nonrandomized study of 830 patients…also found a similar result for celecoxib (Celebrex) and rofecoxib (Vioxx). …
…after a median follow-up of 2.4 years, the risk or recurrence of colon cancer was 55% lower and the risk of death was 48% lower among regular aspirin users compared with nonusers. Patients who used celecoxib or rofecoxib had a 44% reduced risk of recurrence. …

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000